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Objectives. To investigate the role of adrenomedullin the 
pathophysiology of heart failure, we measured plasma levels of 
adrenomedullin i  patients with heart failure. 
Background. Adrenomeduilin s a potent hypotensive peptide 
newly discovered in pheochromocytoma tissue by monitoring its 
elevating activity on platelet adenosine 3',5'-cyclic monophos. 
phate (cAMP). A significant level of adrenomedullin has been 
identified in human plasma. These findings uggest the possibility 
of adrenomedullin asa new circulating hormone that participates 
in the regulation of the cardiovascular system. 
Methods. Venous blood samples at rest were obtained from 
patients with heart failure in New York Heart Association func- 
tional classes I (n = 15), II (n = 25), HI (n = 16) and IV (n = 10) 
and from normal subjects (n = 27). Plasma adrenomedullin evels 
were determined by our newly developed radioimmnnoassay. 
Other humoral factor levels measured simultaneously included 
norepinephrine, atrial natriuretic peptide, brain natriuretic pep. 
fide, plasma renin activity, aidosterone and cAMP. Left ventric. 
ular ejection fraction was measured by echocardiography. In eight 
patients with severe heart failure, plasma adrenomedullin levels 
were measured before and after treatment. 
Results. The mean (±SD) plasma level of adrenomedullin i
control subjects was 2.52 -+ 0.75 pmol/liter. Plasma levels of 
adrenomedullin i  patients with heart failure were unaffected in
those in functional class I (2.85 ~- 0.62 pmol/iiter) but tended to be 
increased in those in class II (3.54 +- 0.82 pmol/iiter) and were 
significantly increased in those in classes III and IV (4.78 ± 1.218 
and 8.74 ± 3.42 pmol/liter, respectively). There was a significant 
correlation between plasma levels of adrenomedullin a d norepi- 
nephrine (r = 0.618, p < 0.001), atrial natriuretic peptide (r = 
0.696, p < 0.001) and brain natriuretic peptide (r = 0.692, p < 
0.001). Left ventricular ejection fraction inversely correlated with 
plasma adrenomedullin levels (r = 0.485, p < 0.001). Plasma 
adrenomedullin levels significantly decreased after treatment 
(from 7.40 ± 3.40 to 3.98 ± 1.00 pmol/iiter, p < 0.05). 
Conclusions. These results suggest that plasma levels of ad- 
renomednllin are elevated in heart failure and that an increased 
plasma volume and an activated sympathetic nervous ystem in 
this condition may be related to its synthesis or secretion. Given 
that adrenomedullin exerts potent cardiovascular effects, in. 
creased adrenomedullin may be involved in the defense mecha- 
nism against further peripheral vascular esistance levation in 
heart failure. 
(J Am Coil Cardiol 1995;26:1424-30 
Adrenomedullin, a novel hypotensive peptide that was discov- 
ered in human pheoehromocytoma by the monitoring of 
platelet adenosine 3',5'-cyclic monophosphate (cAMP) activity 
(1) consists of 52 amino acids with an intramolecular disulfide 
bond forming a ring structure of six residues. It has a slight 
homology with calcitonin gene-related peptide and amylin. 
The hypotensive effects of adrenomedullin are as strong as that 
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of calcitonin gene-related peptide, one of the most potent 
vasorelaxant peptides (1). Immunoreactive adrenomedullin 
has been detected inhuman plasma, and human adrenomedul- 
lin messenger RNA is reported to be highly expressed not only 
in pheochromocytoma, but also in the normal adrenal medulla, 
kidney, lung and ventricle (2). Recent studies (3,4) report hat 
vascular smooth muscle cells possess pecific adrenomedullin 
receptors that are functionally coupled to adenylate cyclase. 
These findings uggest that adrenomedullin may be involved in 
control of the circulation. 
Congestive heart failure is a complex clinical syndrome that 
is characterized by the activation of several neuroendocrine 
systems (5). In the present study, we measured plasma levels of 
adrenornedullin in patients with heart failure using our newly 
developed radioimmunoassay (6) to determine whether ad- 
renornedullin may play a role in this disorder. In addition, we 
simultaneously measured other neurohumoral f ctors to inves- 
tigate their relation to adrenomedullin. 
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Table 1. Clinical Characteristics of Study Patients and Control Subjects 
Patients With Heart Failure (New York Heart Association 
functional class) 
Control 
Group Class I Class II Class III Class IV 
(n = 27) (n = 15) (n = 25) (n = 16) (n = 10) 
Age (yr) 53 +_ 13 58 -+ 11 63 _+ 10 61 _+ 15 68 2 17 
Gender (M/F) 16/11 12/3 16/9 10/6 7/3 
Primary cause of HF 
IHD 5 14 5 2 
Valvular 2 9 7 4 
HHD 6 0 2 0 
DCM 0 0 1 3 
Congenital 0 2 1 0 
Other 2 0 0 1 
Sodium (mmol/liter) 148 + 3 148 +_ 5 143 2 3 144 + 4 141 z 6 
Potassium (mmol/liter) 4.0 +_ 0.4 4.5 _+ 0.3 4.2 2 0.4 4.3 2 0.5 4.2 2 0.6 
Chloride (mmol/liter) 101 _+ 3 100 _+ 6 103 -- 5 104 _+ 5 104 +_ 
MAP (mm Hg) 87 _+ 10 99 _+ 15" 93 _+ 12t 91 _+ 14t 89 _+ 
HR (beats/min) 67 _+ 8 66 _+ 9 69 _+ 7 71 _ 13 79 + 
LVEF 0.67 _+ 0.08 0.57 _+ 0.111" 0.47 _ 0.17:~§ 0.36 _+ 
5 
12:~ 
8":I:11¶ 
o.18:~11'H 
*p < 0.01 versus control group, tP < 0.05, :~p < 0.01 versus functional class I. §p < 0.05, lip < 0.01 versus functional 
class II. ¶p < 0.05 versus functional class Ill. Data presented are mean value _+ SD or number of patients. DCM = dilated 
cardiomyopathy; F = female; HF = heart failure; HHD - hypertensive h art disease; HR = heart rate; IHD = ischemic 
heart disease; LVEF = left ventricular ejection fraction; M = male; MAP = mean arterial pressure; Other = 
hypertrophic cardiomyopathy and constrictive pericarditis. 
Methods 
Study patients. A total of 66 Japanese patients with heart 
failure were enrolled in the study (45 men, 19 women; range 28 
to 86 years old, mean [+SD] 62 + 13) (Table 1) and classified 
into four groups according to cardiac symptoms by New York 
Heart Association functional class: class I = 15 patients (12 
men, 3 women) mean age 58 _+ 11 years; class//= 25 patients 
(16 men, 9 women) mean age 63 _+ 10 years; class III = 16 
patients (10 men, 6 women) mean age 61 _+ 15 years; and class 
/V = 10 patients (7 men, 3 women) mean age 68 _+ 17 years. 
Patients with renal failure (serum creatinine l vel >283 jxmol/ 
liter) or a history of renal disease were excluded. The primary 
cause of heart failure was ischemic heart disease in 26 patients; 
valvular heart disease in 22 (10 with mitral stenosis, 6 with 
mitral regurgitation, 3 with aortic regurgitation, 3 with aortic 
regurgitation a d aortic stenosis); hypertensive heart disease in 
8; dilated cardiomyopathy in 4; congenital heart disease in 3 (2 
with patent ductus arteriosus, 1with transposition fthe great 
arteries); hypertrophic cardiomyopathy in 2; and constrictive 
pericarditis in 1. All patients with symptomatic heart failure 
were receiving medical therapy, including digitalis and diuretic 
drugs. In 5 of 10 patients in functional class IV and 3 of 16 
patients in functional class III, plasma adrenomedullin a d 
atrial and brain natriuretic peptide levels were repeatedly 
evaluated after their symptoms had lessened by treatment. 
Twenty-seven healthy subjects (16 men, 11 women; age 
range 29 to 69 years, mean age 53 _+ 13) served as the control 
group. 
Blood sampling. Blood samples were drawn from all sub- 
jects after their informed consent had been obtained. Before 
blood sampling, heart rate and blood pressure were measured 
in the moming (8 to 9 AM) after an overnight fast and after 
30 min of supine rest. Then, 15 ml of blood was withdrawn 
through the antecubital vein. Blood was immediately trans- 
ferred into two chilled glass tubes, one containing disodium 
ethylenediaminetetraacedic aci  (EDTA) (1 mg/ml) for mea- 
surement of plasma renin activity and plasma aldosterone, 
plasma norepinephrine and plasma cAMP levels and the other 
containing disodium EDTA (1 mg/ml) and aprotinin 
(500 U/ml) for measurement of plasma atrial and brain 
natriuretic peptide and adrenomedullin levels. Blood was 
centrifuged immediately at 4°C and the plasma frozen and 
stored at -80°C until assay. 
In five patients in functional c ass IV and three in functional 
class III, blood samples were drawn again after treatment 
(mean interval 14 +_ 2 days). Plasma drenomedullin a d atrial 
and brain natriuretic peptide levels were repeatedly measured. 
Assay for plasma adrenomedullin concentration. Plasma 
samples that had been stored at -80°C were extracted before 
radioimmunoassay. Sep-Pak C18 cartridges (Millipore- 
Waters) were prewashed sequentially with 5 ml each of 
chloroform, methanol, 50% acetonitrile containing 0.1% tri- 
fluoroacetic acid, 0.1% trifluoroacetic acid and saline solution. 
Two milliliters of plasma was acidified with 24/~1 of 1 mol/liter 
hydrochloric acid and diluted with 2 ml of saline solution and 
then loaded onto a Sep-Pak C18 cartridge. After being washed 
with 5 ml each of saline solution, 0.1% trifluoroacetic a id, and 
20% acetonitrile containing 0.1% trifluoroacetic acid, the 
absorbed materials were eluted with 4 ml of 50% acetonitrile 
containing 0.1% trifluoroacetic acid. The eluate was then 
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lyophilized. For assay, the lyophilized material was dissolved in 
radioimmunoassay buffer, and the clear solution was submitted 
to radioimmunoassay. The radioimmunoassay for ad- 
renomedullin has been reported previously (6). In brief, the 
radioimmunoassay buffer consisted of 0.05 mol/liter sodium 
phosphate buffer (pH 7.4) containing 0.5% bovine serum 
albumin, 0.5% Triton X-100, 0.08 mol/liter sodium chloride, 
0.025 mol/liter disodium ethylenediaminetetraacetic acid, 
0.05% sodium azide and 500 kallikrein inhibiting unit/ml 
aprotinin. Assay procedures were performed at 4°C. Standard 
adrenomedullin orunknown samples (100 t~l) were incubated 
with anti-adrenomedullin a tiserum diluent (200/zl) for 12 h; 
then the tracer solution (18,000 to 20,000 cpm in 100 ill) was 
added. After incubation for 36 h, anti-rabbit immunoglobulin 
G goat serum diluent (100/zl) was added. After standing for 
24 h, the tubes were centrifuged at 2,000 x g for 30 min at 4°C. 
Radioactivity of the precipitate was measured with a gamma 
counter. The half of maximal inhibition of radioiodinated 
ligand binding by adrenomedullin was observed at 4 frnol/tube; 
0.5 to 32 fmol/tube of adrenomedullin was measurable by this 
radioimmunoassay system. The intraassay and interassay coef- 
ficients of variance were 5% and 8%, respectively. The radio- 
immunoassay had 100% cross-reactivity with the methionine 
sulfoxide form of adrenomedullin but only 2% and 0.5% 
cross-reactivity with adrenomedullin [13-52] and adrenomedullin 
[40-52], respectively. It had less than 0.01% cross-reactivity with 
adrenomeduUin [1-12] and adrenomedullin [13-31]. These data 
indicate that the antibody recognizes the entire adrenomedullin 
molecule. 
Assays for other hormones and metabolites. Radioimmu- 
noassay was performed to measure plasma levels of atrial 
natriuretic peptide (Shiono RIA assay kit, Shionogi Co., Ltd., 
Osaka, Japan); brain natriuretic peptide (S-1215, Shionogi); 
cAMP (cyclic AMP assay kit, Yamasa Shoyu, Co., Ltd., Chiba, 
Japan); aldosterone (aldosterone assay kit, Shionogi); and 
plasma renin activity (Renin RIA Beads, Dinabot Co., Ltd., 
Osaka, Japan). Plasma levels of norepinephrine were deter- 
mined by high performance liquid chromatography. Plasma 
electrolyte l vels were measured by the ion-selective method. 
Plasma levels of adrenomedullin and atrial and brain natri- 
uretic peptide were measured in all control subjects and in 
patients with heart failure. Plasma levels of norepinephrine, 
aldosterone, cAMP and plasma renin activity were measured 
in 14 of 27 control subjects, all 15 patients in functional class I, 
21 of 25 in class II, 12 of 16 in class III and 7 of 10 in class IV. 
Eehocardiography. All patients were studied in the decu- 
bitus position using standard echocardiographic technique 
during admission. An M-mode echocardiogram was recorded 
with two-dimensional monitoring using a Hewlett-Packard 
77020A phased-array ultrasound sector scanner or Toshiba 
SSH 160A echocardiographic system (Toshiba, Tokyo, Japan) 
with a 2.5- or 3.75-MHz transducer. Standard echocardio- 
graphic variables, including end-diastolic and end-systolic left 
ventricular dimensions, were determined according to the 
recommendation f the American Society of Echocardiogra- 
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Figure 1. Rest venous plasma levels of adrenomedullin in patients 
with heart failure (functional classes I to IV) and normal control 
subjects (N). NYHA -- New York Heart Association. 
phy (7). Left ventricular ejection fraction was calculated by the 
standard formula. 
Statistics• Data are expressed as mean values +_ SD. 
Comparisons between groups were performed by one-way 
analysis of variance. The significance of the differences be- 
tween the mean values in the control group and each func- 
tional class group was tested with the Tukey multiple compar- 
ison test. Correlation coefficients were calculated by linear 
regression analysis. Comparisons between before and after 
treatment were done by Wilcoxon signed-rank test. A p value 
<0.05 was considered statistically significant. 
Results  
Plasma levels of adrenomedullin. Plasma levels of ad- 
renomedullin patients with heart failure and control subjects 
are shown in Figure 1 and Table 2. Plasma levels of ad- 
renomedullin were unaffected in patients in functional class I 
and tended to be increased in those in functional class II, not 
significantly different from levels in control subjects (2.52 _+ 
0.75 pmol/liter). However, there was a significant increase in 
plasma levels of adrenomedullin i  patients in functional 
classes III and IV. 
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Table 2. Plasma Levels of Neurohumoral Factors in Study Patients and Control Subjects 
Patients With Heart Failure (New York Heart Association functional c ass) 
Control 
Group Class I Class II Class II1 Class IV 
(n = 27) (n = 15) (n = 25) (n = 16) (n = 10) 
Adrenomedullin (pmol/liter) 2.52 ± 0.75 2.85 ± 0.62 3.54 +_ 0.82 4.78 = 1.28"t'2; 8.74 ± 3.42*?§¶ 
Norepinephrine (ng/liter) 173 z 89 281 ± 114 286 _+ 183 493 -+ 234* 877 ,+ 618*t§rl 
ANP (ng/liter) 15 __. 7 28 +- 19 34 ,+ 24 125 ,+ 94't§ 420 ,+ 718'#3 
BNP (rig/liter) ll ± 8 40 ± 40 99 _+ 145 492 _+ 402"t§ 801 ,+ 921'~'§ 
Aldosterone (ng/liter) 99 ± 47 78 ,+ 50 75 -- 44 119 -- 131 278 z 502*?§¶ 
PRA (t~g/liter per h) 1,7 ± 1.2 2.1 ,+ 2.1 2.0 -2-_ 1.6 4.0 ± 4.0 6.0 ~ 7.8"?[I 
cAMP (nmol/liter) 15 ~ 2 15 -+ 6 15 ,+ 5 18 ,+ 8 20 ,+ 8 
*p < 0.01 versus control group, tp < 0.01 versus functional c ass I. Sp < 0.05, §p < 0.01 versus functional c ass I1. lip < 0.05, ¶p < 0.01 versus functional c ass IIl. 
Data presented are mean value _+ SD. ANP = atrial natriuretic peptide; BNP = brain natriuretie peptide; cAMP = adenosine Y,5'-cyclic monophosphate; PRA = 
plasma renin activity. 
Plasma levels of norepinephrine, atrial and brain natri- 
uretic peptide, aldosterone, cAMP and plasma renin activity. 
Plasma levels of humoral factors in control subjects and 
patients with heart failure are shown in Table 2. For norepi- 
nephrine and atrial and brain natriuretic peptide, a graded 
increase in plasma levels was observed according to severity of 
heart failure. There were no significant differences in plasma 
levels of aldosterone and plasma renin activity between control 
subjects and patients with heart failure, except for those in 
functional class IV. There was no significant difference in 
plasma levels of cAMP between control subjects and patients 
with heart failure. 
Correlation between plasma levels of adrenomedullin and 
other humoral factors and left ventricular ejection fraction. 
Plasma levels of adrenomedullin correlated strongly with those 
of norepinephrine (r = 0.618, p < 0.001), atrial natriuretic 
peptide (r = 0.696, p < 0.001) and brain natriuretic peptide 
(r = 0.692, p < 0.001) (Fig. 2 to 4, Table 3). Plasma levels of 
adrenomedullin correlated weakly with plasma renin activity 
(r = 0.354, p < 0.005) and cAMP (r = 0.321, p < 0.01) (Table 
3). There was no significant correlation between plasma levels 
of adrenomedullin and aldosterone (Table 3). In addition, 
there was an inverse correlation between plasma ad- 
renomedullin levels and left ventricular ejection fraction (r = 
0.485, p < 0.001) (Fig. 5). 
Plasma adrenomedullin and atrial and brain natriuretic 
peptide levels before and after treatment. Plasma ad- 
renomedullin and atrial and brain natriuretic peptide levels 
before treatment in eight patients with heart failure (five in 
functional class IV, three in functional class III) were 7.41 +_ 
3.40 pmol/liter, 218 _ 201 rig/liter and 540 +_ 463 ng/liter, 
respectively. After treatment, these levels decreased signifi- 
cantly (adrenomedullin 3.98 _+ 1.00, p < 0.05; atrial natriuretic 
peptide 41 _+ 24, p < 0.05; brain natriuretic peptide 135 _ 93, 
p < 0.05) (Fig. 6 to 8). 
Correlation between adrenomedullin and blood pressure. 
No significant correlation between blood pressure and plasma 
levels of humoral factors in patients with heart failure (func- 
tional classes I to IV) was found. In patients with severe heart 
failure (functional class III or IV), some of humoral factors, 
including adrenomedullin, were highly elevated. However, 
there was no correlation between blood pressure and any 
humoral factor, including adrenomeduilin. 
Figure 2. There was a significant correlation between 
plasma levels of adrenomedullin and norepinephrine 
in patients with heart failure (n = 55). 
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Figure 3. There was a significant correlation between 
plasma levels of adrenomedullin a d atrial natriuretic 
peptide (ANP) in patients with heart failure (n = 66). 
Discuss ion 
We measured plasma levels of adrenomedullin  patients 
with heart failure and control subjects using our newly devel- 
oped radioimmunoassay to determine whether adrenomedul- 
lin might play a pathophysiologic role in heart failure. Plasma 
levels of adrenomedullin i creased in proportion to severity of 
heart failure and were significantly increased in patients with 
severe heart failure (functional classes III and IV). In addition, 
plasma levels of adrenomedullin correlated well with plasma 
levels of atrial and brain natriuretic peptides and norepineph- 
rine and were inversely correlated with left ventricular ejection 
fraction. Plasma levels of adrenomedullin significantly de- 
creased after treatment. Thus, the data suggest hat ad- 
renomedullin is increased in patients with moderate to severe 
heart failure, that volume expansion and an activated sympa- 
thetic nervous ystem may be associated with this increase and 
that plasma adrenomedullin levels change in response to the 
pathophysiologic changes of heart failure. 
Physiologic activity of adrenomedullin. Adrenomedullin s 
a hypotensive peptide consisting of 52 amino acids; it was 
discovered in human pheochromocytoma by monitoring plate- 
let cAMP activity (1). It shows slight homology with calcitonin 
gene-related peptide (1). Intravenous injection of human 
adrenomedullin the rat causes a strong and long-lasting 
hypotensive effect by decreasing total peripheral resistance and 
increasing cardiac output (8). Its effect is comparable to that of 
calcitonin gene-related peptide, one of the strongest vaso- 
relaxant peptides (8). A recent report (9) has shown that 
adrenomedullin has a negative inotropic effect in the perfused 
rat heart. Ebara et al. (10) recently reported that intrarenal 
arterial infusion of adrenomedullin i duced renal vasodilation 
and diuresis in dogs. These findings suggest that adrenomedul- 
lin may regulate the canine cardiovascular system. Immunore- 
active adrenomedullin s also found in human plasma (1,6), 
which suggests that adrenomedullin may be involved in the 
control of circulation in humans. 
Source of circulating adrenomedullin. From which organs 
is circulating adrenomedullin derived? Early reports (2,11) 
showed that adrenomedullin messenger RNA is expressed in
pheochromocytoma as well as in the normal adrenal medulla, 
lungs, heart and kidney. These findings suggest that increased 
synthesis and secretion of adrenomedullin may occur in these 
organs during heart failure. We investigated the sites of 
production and clearance of adrenomedullin i  humans to test 
g 
.m 
t~ 
O 
Z 
4000- 
3000- 
2000-  
I000-  
0 
0.0 
y= 136.7x-318.9,  r =0.692, p<0.001  
f J O j 
J o j 
J 
0 0 o 0 ~ ~  ° 0 
o ^ ~ _  o o°  
~ - o 
5.0 11~,0 
Plasma Adrenomedullin Concentration (pmol/l) 
1 
15.0 
Figure 4. There was a significant correlation be- 
tween plasma levels of adrenomedullin and brain 
natriuretic peptide (BNP) in patients with heart 
failure (n = 66). 
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Table 3. Correlation Between Plasma Levels of Adrenomedullin 
and Other Humoral Factors and Left Ventricular Ejection Fraction 
Correlation p 
Coefficient (r) Value 
Norepinephrine 0.618 <0.001 
ANP 0.696 <0.001 
BNP 0.692 <0.001 
Aldosterone 0.070 NS 
PRA 0.354 <0.005 
cAMP 0.321 <0.01 
LVEF 0.485 <0.001 
Abbreviations as in Tables 1 and 2. 
whether these four organs actually release adrenomedullin into 
the circulation (12). We obtained samples of arterial and 
venous blood from the adrenal glands, kidney, lungs and heart 
and measured plasma levels of adrenomedullin in patients with 
ischemic heart disease and hypertension. There was no signif- 
icant increase in adrenomedullin concentration i  the renal 
vein, adrenal vein or coronary sinus compared with that in the 
aorta. Plasma levels of adrenomedullin in the pulmonary artery 
were significantly higher than those in the aorta, suggesting 
that he pulmonary circulation may be a site of adrenomedullin 
clearance, although active secretion sites were not identified 
(12). Sugo et al. (13) recently found that cultured vascular 
endothelial cells actively synthesize adrenomedullin in vitro, 
comparable to the synthesis of endothelin-1. Vascular endo- 
thelial cells produce ndothelin, itric oxide, prostacyclin and 
C-type natriuretic peptide and play an important role in local 
control of vascular tone. Sugo et al. (14) also reported that 
vascular smooth muscle cells also produce and secrete ad- 
renomedullin vitro. Eguchi et al. (3) and Ishizaka et al. (4) 
recently reported that specific receptors for adrenomedullin 
are present in cultured vascular smooth muscle cells. Although 
the source of circulating adrenomedullin in humans is pres- 
ently unknown, these results uggest that adrenomedullin may 
be produced and secreted by the vascular endothelial cells or 
vascular smooth muscle cells, or both, and participate in the 
control of circulation as one of the vascular egulators. 
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Figure 6. Plasma levels of adrenomeduUin before and after treatment 
in patients with heart failure. Plasma levels of adrenomedullin signif- 
icantly decreased after treatment. 
Whether the increase in adrenomedullin picomolar 
concentrations is biologically active remains unknown. Intra- 
venous administration of adrenomedullin at 0.3, 1.0, and 
3 nmol/kg produces a hypotensive ffect in the rat in a 
dose-dependent manner (1). The expected resultant plasma 
concentration in the rat would be much higher than that found 
in humans. Because intravenously administered a renomedul- 
lin may be degraded or metabolized in part in the pulmonary 
circulation, as we have shown in humans (12), the actual 
plasma concentration may be lower than expected. In fact, the 
direct intraarterial infusion of adrenomedullin into the renal 
artery in the dog at a dose of 0.8 ng/kg body weight per rain has 
a vasodilatory effect (10). The fact that adrenomedullin mes- 
senger RNA is expressed in various organs and that vascular 
endothelial cells and vascular smooth muscle cells synthesize 
and secrete adrenomedullin suggests hat the local concentra- 
tion of adrenomedullin may exceed the circulating level. Taken 
Figure 5. There was a significant inverse correlation 
between plasma levels of adrenomedullin and left ven- 
tricular ejection fraction (LVEF) in patients with heart 
failure (n = 66). 
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Figure 7. Plasma levels of atrial natriuretic peptide (ANP) before and 
after treatment in patients with heart failure. Plasma levels of atrial 
natriuretic peptide significantly decreased after treatment. 
together, these findings indicate that adrenomedullin may act 
mainly as a local rather than a circulating hormone in a 
paracrine or autocrine manner. 
Relation of adrenomedullin with other vasoactive sub. 
stances in heart failure. We observed good correlation be- 
tween plasma levels of adrenomedullin a d atrial natriuretic 
peptide. Atrial natriuretic peptide is released by the atrial 
stretch and serves as an indicator of plasma volume and atrial 
pressure in heart failure (15,16). Accordingly, volume expan- 
sion may also be a stimulus for the synthesis and secretion of 
adrenomedullin in heart failure. This finding is consistent with 
our findings in patients with chronic renal failure (17). Plasma 
levels of adrenomedullin are increased with a concomitant 
increase in serum creatinine l vels and show good correlation 
with plasma trial natriuretic peptide levels (17). In the present 
Figure 8. Plasma levels of brain natriuretic peptide (BNP) before and 
after treatment in patients with heart failure. Plasma levels of brain 
natfiuretic peptide significantly decreased after treatment. 
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study, there was also good correlation between plasma levels of 
adrenomedullin a d brain natriuretic peptide in heart failure. 
Brain natriuretic peptide, like atrial natriuretic peptide, is 
known to increase in proportion to the severity of heart failure 
(18). Like atrial natriuretic peptide, brain natriuretic peptide 
has natriuretic and vasorelaxant actions (19); however, brain 
natriuretic peptide is derived mainly from the ventricle and is 
secreted principally in response to ventricular overload. Thus, 
the significant correlations between adrenomedullin a d dual 
natriuretic peptides, indicators of volume expansion, may be 
consistent with the hypothesis that volume overload is one of 
the stimuli for adrenomedullin release in heart failure. This 
hypothesis may be supported by the finding that plasma levels 
of adrenomedullin significantly decreased after treatment in
patients with severe heart failure. With a reduction in plasma 
adrenomedullin levels, plasma atrial and brain natriuretic 
peptide levels significantly decreased. 
We observed amoderate correlation between plasma levels 
of adrenomedullin a d norepinephrine. It is known that the 
plasma levels of norepinephrine are increased in heart failure 
and serve as an indicator of prognosis in heart failure (20). 
These findings suggest that an activated sympathetic nervous 
system may be related to increased adrenomedullin levels, 
which would be consistent with our observation i patients with 
chronic renal failure (17). We recently reported (21) the 
genomic structure of the human adrenomedullin gene. The 
5'-flanking region in the human adrenomedullin gene contains 
multiple binding sites for activator protein-2 (AP-2) and a 
cAMP-regulated enhancer element. These findings indicate 
that the expression of the adrenomedullin gene may be subject 
to the activity of protein kinase C and cAMP levels. Norepi- 
nephrine is known to activate protein kinase C and phospho- 
lipase C through the alphal-receptor. Therefore, increased 
plasma norepinephrine levels in heart failure may affect the 
gene expression of adrenomedullin through the alpha l- 
receptor. The exact mechanism ofadrenomedullin release and 
the relation between adrenomeduUin a d norepinephrine r - 
quires further study. 
We also observed weak correlations between plasma levels 
of adrenomedullin a d cAMP and plasma renin activity. The 
renin-angiotensin ystem as well as the sympathetic nervous 
system is activated in heart failure (22). Therefore, an activated 
renin-angiotensin ystem and sympathetic nervous ystem may 
be associated in part with increased plasma levels of ad- 
renomedullin patients with heart failure, cAMP is a second 
messenger ofnorepinephrine, epinephrine and vasopressin, all 
of which are elevated in heart failure. Because the second 
messenger ofadrenomedullin may be considered to be cAMP, 
an increased adrenomedullin evel may contribute, in part, to 
an increased plasma level of cAMP in heart failure. 
In the present study, there was an inverse correlation 
between plasma adrenomedullin levels and left ventricular 
ejection fraction. Left ventricular ejection fraction is a left 
ventricular systolic index and is known to be inversely corre- 
lated with plasma atrial and brain natriuretic peptide levels 
(23). Therefore, plasma levels of adrenomedullin in patients 
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with heart failure may indirectly reflect left ventricular func- 
tion. Although the correlation coefficient was significant, albeit 
relatively weak, this may be partially explained by the fact that 
some of the patients with severe heart failure reflect a state of 
circulatory congestion rather than left ventricular dysfunction. 
There was no correlation between plasma adrenomedull in 
levels and blood pressure in patients with heart failure, nor did 
other humoral factors correlate with blood pressure. There was 
no significant relation between blood pressure and humoral 
factors, even in patients with severe heart failure who had 
higher plasma adrenomedull in evels. Thus, it seems that blood 
pressure is not regulated by one humoral factor but by multiple 
factors in heart failure. 
Conclusions. The present study demonstrated a significant 
and proportionate increase in plasma levels of adrenomedull in 
in patients with moderate to severe heart failure. In addition, 
we observed a significant correlation between plasma levels of 
adrenomedullin, orepinephrine, and atrial and brain natri- 
uretic peptides. Plasma levels of adrenomedull in patients 
with severe heart failure decreased after treatment, with a 
concomitant decrease in atrial and brain natriuretic peptide 
levels. Our results suggest hat the increased plasma volume 
and an activated sympathetic nervous ystem may be involved 
in the increased levels of circulating adrenomedullin. Given 
that adrenomedull in exerts potent cardiovascular effects in 
animal models and that vascular endothelial cells and vascular 
smooth muscle cells synthesize and secrete adrenomedullin, 
increased adrenomedull in i  heart failure may be involved in 
the defense mechanism against further elevation in peripheral 
vascular esistance. 
We thank Yoko Saito for technical ssistance. 
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